Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains
- PMID: 12810872
- DOI: 10.1099/vir.0.19088-0
Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains
Abstract
Formaldehyde-inactivated virus samples from type 1 poliovirus live-attenuated strains were prepared in the laboratory. The effect of treatment with formaldehyde on virus infectivity and immunogenicity in mice was investigated and the results compared with those from Mahoney wild-type poliovirus strain, the common type 1 component in commercial inactivated polio vaccines (IPV). Differences in the potency and specificity between these experimental vaccines were identified in both normal mice and transgenic mice expressing the human poliovirus receptor. The possible advantages/disadvantages of using live-attenuated strains for IPV production are discussed in the context of the global polio eradication initiative. A novel transgenic mouse model to study in vivo the immune protection induced by IPV preparations is described.
Similar articles
-
Inactivated poliovirus vaccine protects transgenic poliovirus receptor mice against type 3 poliovirus challenge.J Infect Dis. 1997 Feb;175(2):441-4. doi: 10.1093/infdis/175.2.441. J Infect Dis. 1997. PMID: 9203668
-
Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays.J Infect Dis. 2020 Feb 3;221(4):544-552. doi: 10.1093/infdis/jiz076. J Infect Dis. 2020. PMID: 30788503
-
Further development of a new transgenic mouse test for the evaluation of the immunogenicity and protective properties of inactivated poliovirus vaccine.J Infect Dis. 2006 Sep 15;194(6):804-7. doi: 10.1086/506949. Epub 2006 Aug 16. J Infect Dis. 2006. PMID: 16941347
-
Vaccinology of poliomyelitis.Vaccine. 1984 Mar;2(1):59-74. doi: 10.1016/s0264-410x(98)90035-4. Vaccine. 1984. PMID: 6099644 Review.
-
Risks associated with the use of live-attenuated vaccine poliovirus strains and the strategies for control and eradication of paralytic poliomyelitis.Expert Rev Vaccines. 2012 May;11(5):609-28. doi: 10.1586/erv.12.28. Expert Rev Vaccines. 2012. PMID: 22827246 Review.
Cited by
-
Neonatal Murine Model of Coxsackievirus A2 Infection for the Evaluation of Antiviral Therapeutics and Vaccination.Front Microbiol. 2021 May 28;12:658093. doi: 10.3389/fmicb.2021.658093. eCollection 2021. Front Microbiol. 2021. PMID: 34122374 Free PMC article.
-
Immune and Safety Analysis of ultraIPVTM, a Novel UVC-Inactivated Polio Vaccine.Viruses. 2025 Jun 27;17(7):915. doi: 10.3390/v17070915. Viruses. 2025. PMID: 40733533 Free PMC article.
-
Comprehensive profiling of neutralizing polyclonal sera targeting coxsackievirus B3.Nat Commun. 2023 Oct 12;14(1):6417. doi: 10.1038/s41467-023-42144-2. Nat Commun. 2023. PMID: 37828013 Free PMC article.
-
Effect of formaldehyde inactivation on poliovirus.J Virol. 2014 Oct;88(20):11955-64. doi: 10.1128/JVI.01809-14. Epub 2014 Aug 6. J Virol. 2014. PMID: 25100844 Free PMC article.
-
Twenty-Eight Years of Poliovirus Replication in an Immunodeficient Individual: Impact on the Global Polio Eradication Initiative.PLoS Pathog. 2015 Aug 27;11(8):e1005114. doi: 10.1371/journal.ppat.1005114. eCollection 2015 Aug. PLoS Pathog. 2015. PMID: 26313548 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials